EA201991582A2 - Subcutaneous administration of conjugates of blood factors with polyethylene glycol - Google Patents

Subcutaneous administration of conjugates of blood factors with polyethylene glycol

Info

Publication number
EA201991582A2
EA201991582A2 EA201991582A EA201991582A EA201991582A2 EA 201991582 A2 EA201991582 A2 EA 201991582A2 EA 201991582 A EA201991582 A EA 201991582A EA 201991582 A EA201991582 A EA 201991582A EA 201991582 A2 EA201991582 A2 EA 201991582A2
Authority
EA
Eurasian Patent Office
Prior art keywords
coagulation factor
polyethylene glycol
residue
dosage form
conjugates
Prior art date
Application number
EA201991582A
Other languages
Russian (ru)
Other versions
EA201991582A3 (en
Inventor
Вильям Генри
Ричард Вольф-Гаррэвэй
Джон Чарльз Майо
Майкл Джеймс Эрл
Original Assignee
Кантаб Биофармасьютикалз Пэтентс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кантаб Биофармасьютикалз Пэтентс Лимитед filed Critical Кантаб Биофармасьютикалз Пэтентс Лимитед
Publication of EA201991582A2 publication Critical patent/EA201991582A2/en
Publication of EA201991582A3 publication Critical patent/EA201991582A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к применению лекарственной формы фактора свертывания крови для лечения заболевания, связанного со свертываемостью крови, или повреждения, где указанная лекарственная форма содержит фармацевтическую композицию фактора свертывания крови, представляющего собой фактор IX, конъюгированного с молекулой полиэтиленгликоля (ПЭГ), причем молекула ПЭГ конъюгирована непосредственно или опосредованно с фактором свертывания крови через остаток серина или треонина, через остаток гидроксила на остатке сахара, через единственный остаток цистеина, через амид, N-концевую аминогруппу или карбоксильную группу, причем дозировка фактора свертывания крови составляет от 1 до 1000 МЕ/кг, причём лекарственную форму вводят подкожно.The present invention relates to the use of a coagulation factor dosage form for the treatment of a disease associated with blood coagulability or damage, wherein said dosage form comprises a pharmaceutical composition of a coagulation factor of factor IX conjugated to a polyethylene glycol molecule (PEG), wherein the PEG molecule is conjugated directly or indirectly with the coagulation factor through a serine or threonine residue, through a hydroxyl residue on a sugar residue, through a single cysteine residue, through an amide, an N-terminal amino group or a carboxyl group, wherein the dosage of blood coagulation factor is from 1 to 1000 IU / kg, moreover, the dosage form is administered subcutaneously.

EA201991582A 2012-08-22 2013-04-16 Subcutaneous administration of conjugates of blood factors with polyethylene glycol EA201991582A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1214985.2A GB201214985D0 (en) 2012-08-22 2012-08-22 Modified therapeutic agents

Publications (2)

Publication Number Publication Date
EA201991582A2 true EA201991582A2 (en) 2019-12-30
EA201991582A3 EA201991582A3 (en) 2020-02-28

Family

ID=47017163

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991582A EA201991582A3 (en) 2012-08-22 2013-04-16 Subcutaneous administration of conjugates of blood factors with polyethylene glycol

Country Status (2)

Country Link
EA (1) EA201991582A3 (en)
GB (1) GB201214985D0 (en)

Also Published As

Publication number Publication date
GB201214985D0 (en) 2012-10-03
EA201991582A3 (en) 2020-02-28

Similar Documents

Publication Publication Date Title
EA033469B1 (en) Subcutaneous administration of blood factor conjugates with polyethylene glycol
BR112012029975A2 (en) peptide as a medicine, in particular for the treatment of cancer.
EA201790871A1 (en) TARED CONJUGATE COMPOSITIONS XTEN AND METHODS FOR THEIR PRODUCTION
MX2017004592A (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs.
EA201270167A1 (en) DOSAGE FORM OF GLETIRAMER ACETATE WITH A REDUCED VOLUME AND METHODS OF INTRODUCTION
AR081042A1 (en) PEPTIDES OF THE GLUCAGON SUPERFAMILY PRESENTING ACTIVITY OF THE RECEPTOR COUPLED TO PROTEINS G
EA201491285A1 (en) IMPROVED COMPOSITIONS AND METHODS OF DELIVERY OF OMEPRAZOL AND ACETYLSALICYLIC ACID
EA201370178A1 (en) STABLE COMPOSITIONS FOR PARENTERAL INJECTION OF PEPTIDE MEDICINES
BRPI0520032A2 (en) molecules to carry a compound through the blood brain barrier
BR112015011179A2 (en) stable aqueous compositions comprising human insulin or an analog or derivative thereof
EA201170527A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING BORONIC ACID COMPOUNDS
EA201270683A1 (en) COMPOSITIONS IN THE FORM OF LYOPHILIZED KEKA
EA201792487A1 (en) COMPOSITIONS OF HYDROXYPROPYL-BET-CYCLODEXTRINS AND METHODS
JP2013503165A5 (en)
PH12014501937A1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
BR112021006167A8 (en) RNA PARTICLES COMPRISING POLYSARCOSINE
ATE507818T1 (en) ORAL ADMINISTRATION OF A CALCITONIN
EP4218769A3 (en) Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose
FI3229828T3 (en) Insulin glargine/lixisenatide fixed ratio formulation
RU2015116264A (en) COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN PATIENTS WITH DIABETES
MX353649B (en) Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery.
EA201391063A1 (en) APOLIPOPROTEIN A-IV AS ANTIDIABETIC PEPTIDE
PE20130782A1 (en) PHARMACEUTICAL COMPOSITIONS CONSISTING OF PARACETAMOL AND THE PROCESS FOR THE PREPARATION OF THE SAME
WO2012138911A3 (en) Conjugates of anti-hiv drugs and somatostatin analogs
EA201991582A2 (en) Subcutaneous administration of conjugates of blood factors with polyethylene glycol